Somatic Mutation Testing
Testing for the presence of cancer requires the utmost personal care and consideration. Somatic mutation testing is enormously beneficial for improving the prognosis and the quality of life of cancer-affected patients. Our team of hereditary and somatic cancer experts will support you during every step of the process.
Every cancer cell can evolve its own pattern of mutated genes.
Each person's cancer, and even parts of a single tumor, can become completely unique. This has implications with respect to diagnosis, prognosis and treatment response. The presence of recurrent somatic mutations allows us to create a detailed molecular fingerprint of the tumor and to identify important tumor subtypes.
Why Choose CENTOGENE?
Distinctive product offering centered around high-quality genetic testing
Strong presence in and access to countries with a high prevalence of rare diseases
CentoCard provides easy logistics for central testing
Rare disease-centric Bio/Databank generates best-in-class medical insights
Deep expertise in rare, metabolic, and neurodegenerative diseases, as well as multiomics enables better diagnostics
Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patients tumor profile.
Cancer is one of the leading causes of morbidity and mortality worldwide. Cancer can be the result of a genetic predisposition that is inherited from family members (germline (hereditary) gene mutation) or it can be the result of the acquired mutations accumulated during a lifetime (somatic (acquired) mutation).
Unlike regular cells, cancer cells do not experience physiological elimination of “programmed cell death” or “apoptosis”; instead they continue to grow and divide. Tumor cells show uncontrolled proliferation if there are mutations in the genes involved in cell division .
Hotspot targeted mutation testing is unavailable in the US for the following mutations: BRAF c.1799T>A p.V600E, EGFR c.2573T>G, p.L858R, KRAS c.35G>A, p.G12D, KRAS c.38G>A, p.G13D, KRAS c.35G>T p.G12V, NRAS c.181C>A p.Q61K, NRAS c.34G>T, p.G12C, NRAS c.35G>A, p.G12D, NRAS c.182A>G, p.Q61R.
Mechanistic Insights Into Cancer Predisposition
Genetic predisposition to cancer is tightly linked to an increased rate of somatic mutations. For one of the corresponding syndromes, the underlying defect has now been revealed to affect the DNA […]
‘PICoP global‘ – an international collaboration assessing neoepitopes for patient-specific vaccination in Colon and Pankreas Cancer
This webinar will cover the opportunities and challenges with clinical Whole Genome Sequencing (cWGS), value of curated digital data, re-classification and re-analysis and the utility of cWGS
Is Pancreatitis a Genetic Disease?
Pancreatitis is a common cause of life-threatening abdominal symptoms and pain. If diagnosed, especially in the young, the question as to the etiology arises. Join our guest speaker, Prof. Matthias […]
Complete Oncogenetic Workflow
Looking for a one-stop-solution for your laboratory? Join this webinar to learn more about our CentoCloud® for diagnostic NGS panels, clinical bioinformatics & medical interpretation in the […]